
Accelerate Diagnostics AXDX
Quarterly report 2024-Q3
added 11-07-2024
Accelerate Diagnostics Total Non Current Liabilities 2011-2026 | AXDX
Annual Total Non Current Liabilities Accelerate Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 134 M | 120 M | 21 K | 1 M | 1 M | 1.03 M | 777 K | 986 K | 1.38 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | 21 K | 28.9 M |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Anixa Biosciences
ANIX
|
4.17 M | $ 3.03 | -2.26 % | $ 98.3 K | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 39.83 | 1.7 % | $ 1.11 B | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Brainsway Ltd.
BWAY
|
7.58 M | $ 23.52 | -2.2 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
61.1 M | $ 34.0 | 0.68 % | $ 366 M | ||
|
Exact Sciences Corporation
EXAS
|
981 M | $ 102.43 | 0.13 % | $ 19 B | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 26.13 | -0.44 % | $ 790 M | ||
|
BioNano Genomics
BNGO
|
16.4 M | $ 1.3 | -11.56 % | $ 1.65 M | ||
|
Guardant Health
GH
|
91.4 M | $ 111.99 | 1.37 % | $ 13.7 B | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
3.56 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
26.9 B | $ 218.32 | -0.59 % | $ 160 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 66.61 | -0.1 % | $ 4.61 B | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
1.15 B | $ 73.22 | -1.05 % | $ 28.3 B | ||
|
NeoGenomics
NEO
|
434 M | $ 11.91 | -3.95 % | $ 1.51 B | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 20.33 | -2.26 % | $ 1.09 B | ||
|
Celcuity
CELC
|
69.2 K | $ 108.09 | -3.59 % | $ 4.26 B | ||
|
DarioHealth Corp.
DRIO
|
25.8 M | $ 10.14 | -1.55 % | $ 288 M | ||
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Personalis
PSNL
|
639 K | $ 9.27 | -7.02 % | $ 549 M | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
2.04 B | $ 144.04 | -3.77 % | $ 22.9 B | ||
|
QIAGEN N.V.
QGEN
|
1.58 B | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
13 B | $ 229.24 | -2.71 % | $ 41.6 B | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 208.45 | -1.53 % | $ 10.7 B | ||
|
Thermo Fisher Scientific
TMO
|
22.5 B | $ 575.61 | -2.79 % | $ 220 B | ||
|
Trinity Biotech plc
TRIB
|
106 M | $ 0.81 | -7.96 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
4.56 M | $ 40.92 | -1.59 % | $ 2.45 B | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 581.54 | -1.94 % | $ 18 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 185.97 | 1.99 % | $ 20.6 B | ||
|
Biodesix
BDSX
|
62.1 M | $ 9.61 | -0.57 % | $ 1.25 B | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
1.9 M | $ 24.39 | 0.54 % | $ 31.7 M | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 269.91 | 0.04 % | $ 22.6 B | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 376.67 | -1.16 % | $ 29.2 B | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 179.26 | -3.57 % | $ 14.8 B | ||
|
IDEXX Laboratories
IDXX
|
630 M | $ 673.4 | -0.49 % | $ 55.5 B |